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ABSTRACT 
 
The reaction of aged carboplatin (reaction of carboplatin in 24 mM NaHCO3 for 
45 h, 37
o
 C, pH 8.6) with pBR322 DNA for 0 ≤ r ≤ 2.8, where r = [drug]/[DNA-
bp], in 24 mM HEPES buffer, pH 7.4, for 24 h followed by agarose gel 
electrophoresis showed DNA mobility changes consistent with unwinding closed 
circular DNA.  However, identical experiments conducted in a two buffer system, 
24mM HEPES plus 24mM carbonate, showed no DNA mobility changes, 
indicating that carbonate blocks formation of the 1,2-intrastrand crosslink on 
DNA.  Studies with aged carboplatin and with cisplatin carried out with 2.0 ≤ r ≤ 
10.0 in the two buffer system show that some DNA binding and unwinding occurs 
for both drugs.  Since carbonate inhibits the binding of aged carboplatin and 
cisplatin to DNA, carbonate present in the body likely modulates the reactivity of 
these drugs with a variety of biological targets including DNA.   
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1 
INTRODUCTION 
 
 Platinum drugs have long been used in clinical cancer therapy.  Since the 
serendipitous discovery of the antiproliferative properties of cisplatin, [cis-
Pt(NH3)2Cl2], by Barnett Rosenberg over 30 years ago (1,2), this compound has 
been successfully used in the treatment of ovarian, testicular, and many other 
cancers (3).  However, the drug’s severe side effects, often including kidney and 
nervous system toxicity, severe nausea, and high-frequency hearing loss (4), led 
the search for improved Pt
2+
 anticancer compounds. 
 One of the second-generation drugs developed to ameliorate these 
shortcomings was carboplatin, [cis-Pt(NH3)2(CBDCA-O,O')], where CBDCA is 
cyclobutane-1,1-dicarboxylate.  Clinically, carboplatin is less oto- and 
nephrotoxic than cisplatin (3,5), and is useful against cisplatin-resistant 
malignancies (6).  Carboplatin’s bidentate dicarboxylate chelate makes the drug 
much less reactive than cisplatin, which may partly explain the reduction in side 
effects seen in chemotherapy (7). 
 Electrophilic platinum compounds have been shown to bind DNA in the 
cell, forming mono- and bifunctional adducts (7-9).  It is generally thought that 
such DNA lesions induce apoptosis, destroying cancerous cells, though other 
mechanisms of action have been proposed (10).  Research has shown that 
cisplatin and carboplatin both interact with DNA in roughly the same manner.  
Knox et. al. found in 1986 that, although carboplatin binds DNA at a much slower 
rate than cisplatin, both drugs form the same type of adduct on DNA (5).  Their 
results showed that roughly 100 times as much carboplatin as cisplatin is needed 
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to achieve an equivalent amount of DNA binding, though smaller ratios have been 
reported (11); however, equal binding resulted in equal DNA lesions and 
cytotoxicity for the two drugs.  Further research by Hongo et. al. supported the 
conclusion that the two drugs differ mainly in kinetics, and showed that both 
drugs preferentially target G,G sequences on DNA (6).   
 Reports of carboplatin’s extremely slow reaction with DNA belied the 
drug’s effectiveness in clinical use, leading researchers to look for a possible 
mechanism of activation in vivo.  Carboplatin had been shown to first bind DNA 
monofunctionally as a monoaquo species, with loss of the CBDCA ligand leading 
to formation of a bifunctional adduct (5).  However, the reaction of carboplatin 
with water proceeds extremely slowly (k1 = 7.2 × 10
-7
 s
-1
), indicating that aquation 
might not produce enough of the necessary ring-opened species in vivo to allow 
significant DNA binding (5).  Further, DNA-binding carboplatin species were 
most prevalent under highly basic conditions not seen in the human system (6).  
Though direct interaction between unmodified carboplatin and DNA had been 
suggested (7,11), investigation into activation mechanisms which could produce 
ring-opened carboplatin species in vivo began. 
 One proposed activating agent was carbonate, found in equilibrium with 
bicarbonate, carbonic acid, and aqueous carbon dioxide and present at high 
concentration (23.8mM) in the blood (12,13).  Carbonate has been shown to play 
an important role in the cellular uptake and toxicity of Ti
4+
, Pb
2+
 and Cd
2+
 (14-
16), and carbonato complexes of Pd
2+
 were shown to form via substitution by 
HCO3
-
 or CO3
2-
 (17).  Early studies showing carbonate’s ability to displace 
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ligands from Pt
2+
 compounds indicated a possible role in platinum anticancer 
treatment (18).   
 The Dabrowiak Lab has investigated carbonate interactions with platinum 
drugs extensively.  In 2005, Centerwall et. al. used 
13
C NMR to show that a 
carbonate-modified  cisplatin species forms when the drug is incubated in 
carbonate-containing tissue culture medium (19).  Further study has shown that 
Jurkat cells are able to defend against cisplatin attack via production of a drug-
modifying extracellular substance (20). 
 A study of the effect of carbonate on the DNA binding of cisplatin was 
also undertaken.  Binter et. al. showed that a physiologically relevant amount of 
carbonate drastically alters the binding of cisplatin to pBR322 plasmid DNA, and 
it was theorized that carbonate leads to monofunctional adduct formation (21).  
While this theory was challenged by Todd et. al. (22), who suggested that 
carbonate mainly affects the rate of formation of the conventional 1,2-intrastrand 
bifunctional adduct, Binter’s results nonetheless indicate that carbonate may play 
a large role in cisplatin activity in vivo. 
 The interaction between carboplatin and carbonate has also been studied 
by Dabrowiak and coworkers.  In 2006, Di Pasqua et. al. used HSQC NMR to 
show that carboplatin is attacked by carbonate at physiological pH to produce a 
mixture of ring-opened anionic carbonato species (23).  It was theorized that these 
ring-opened species could be the active agents responsible for carboplatin’s 
anticancer activity in the body, and that carbonate ion is the attacking nucleophile 
responsible for activating the drug in vivo.  This was supported by Di Pasqua’s 
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2007 finding that carbonate-aged carboplatin is more cytotoxic to human 
neuroblastoma, proximal renal tube, and Namalwa-luc Burkitt’s lymphoma cells 
than the native drug (24).  It was also seen that Jurkat cells produce an 
unidentified extracellular substance which modifies carboplatin (25), similar to 
the defense mechanism against cisplatin reported by Dabrowiak and coworkers 
(20). 
 In this study, we sought to determine the effect of carbonate on the DNA 
binding of carbonate-activated carboplatin.  We followed the carbonate aging 
procedure outlined by Di Pasqua (23,24), providing the full variety of carbonato-
carboplatin species thought to develop under physiological conditions.  By 
carrying out DNA binding in a carbonate-rich solution, we modeled the 
environment of cellular DNA in vivo.  We used closed-circular plasmid DNA as 
our binding target, and measured the extent of binding through agarose gel 
electrophoresis, a benchmark technique in the study of platinum-DNA binding 
(5,6,9).  We found that physiologically-relevant concentrations of carbonate in the 
DNA environment prevented binding of carbonate-aged carboplatin. 
 We then broadened the conditions of the study, using higher molar ratios 
of both carbonate-aged carboplatin and cisplatin to determine whether carbonate 
changed the mode of DNA binding, the rate, or both.  We found that carbonate’s 
limiting effect on DNA binding could be overcome by high molar ratios of both 
drugs, indicating that the 1,2-intrastrand crosslink could still form in the presence 
of carbonate.  These findings were published in 2008 (26). 
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 We then attempted to quantify the carbonate effect.  We sought to 
determine, using mass spectrometry, the amount of platinum bound to DNA in the 
presence and absence of carbonate, in order to obtain a rate for platinum-DNA 
binding in a carbonate-rich environment.  Several tries at measuring the binding 
using this technique proved inconclusive.  Additionally, we did a preliminary 
study using ethanol precipitation to isolate platinated DNA for binding 
measurement, but this was also unsuccessful. 
 Despite these difficulties in gathering quantitative data, our findings 
indicate that carbonate greatly reduces the rate of DNA binding of both cisplatin 
and carbonate-activated carboplatin.  We show how platinum drugs, specifically 
the modified species which may form in the blood, interact with DNA in an 
environment similar to that inside the cell, and how this differs from previous 
models.  Since it is critically important to observe how these drugs react under 
conditions of human chemotherapy, our findings may help clarify carbonate’s role 
in the activity of these platinum drugs. 
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MATERIALS & METHODS 
 
Materials:  HEPES, N-(2-hydroxyethyl)-piperazine-N´-2-ethanesulfonic acid; 
sodium bicarbonate, >99% pure; and cisplatin (solid) were purchased from Sigma 
(St. Louis, MO). Carboplatin, 26.9 mM, was from Bedford Laboratories (Bedford, 
OH). Plasmid DNA (pBR322), 25µg/µL, was purchased from Invitrogen 
(Carlsbad, CA), and sodium chloride (A.C.S.) was purchased from Fisher 
Scientific (Pittsburgh, PA).  Ethyl alcohol (190 proof, 95%, A.C.S.) was 
purchased from Pharmco-AAPER (Brookfield, CT), and sodium acetate (A.C.S.) 
was purchased from Fisher Scientific (Fair Lawn, NJ). 
 
Preparation of drug solutions:  A 0.5 M carbonate solution (pH 8.6) was made 
by dissolving solid NaHCO3 in deionized water.  Carboplatin infusion solution 
was added to a final concentration of 26.9 mM, and the resulting solution was 
incubated in a push-top Eppendorf tube for 45 hours at 37°C.  Stock cisplatin 
solution was made by dissolving solid cisplatin in 154 mM NaCl to produce a 3 
mM drug solution which was equilibrated in the dark for 24 hours at room 
temperature. 
 
Reaction of drug with DNA:  Plasmid pBR322 DNA was added to a 
concentration of 9.6 µM in a pH 7.4 buffer solution consisting of either 24 mM 
HEPES plus 24 mM carbonate, or 24 mM HEPES alone.  Appropriate 
concentrations of the drug solutions (carbonate-aged carboplatin or equilibrated 
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cisplatin) were added to give the indicated r-values, where r = [Pt]/[DNA-bp], and 
adjusted with dH2O to a final volume of 20 µL.  The drug-DNA solutions were 
incubated in push-top Eppendorf tubes at 37°C for 24 hours.  In atmosphere-
controlled experiments, screw-top Eppendorf tubes with a rubber o-ring seal were 
used; CO2, argon, or nitrogen gas was blown at low pressure over the drug-DNA 
solution for ~30 seconds and the tubes quickly capped prior to 24 hour incubation. 
 
Ethanol DNA precipitation:  Double-volume binding samples were made (total 
volume = 40 µL, same concentrations as above).  After removal of an 8 µL 
aliquot for gel electrophoresis, sodium acetate was added to each sample to a final 
concentration of 5.1 M, followed by an equal volume of ice-cold ethanol.  Tubes 
were stored on ice 3 hours, then cold centrifuged at 12,000 g for 1 hour. 
 
Gel electrophoresis:  After the drug-DNA incubation, an 8 µL sample of each 
binding experiment was mixed with 1 µL of a 50% glycerol, 0.25% bromphenol 
blue and 0.25% xylene cyanol solution, and 8µL of the resulting solutions were 
loaded onto a 1% agarose gel.  Electrophoresis was carried out at 75V for ~5 
hours in TRIS buffer.  Following electrophoresis, the gels were stained for 30 
minutes in a 10
-4
 % ethidium bromide solution and de-stained in water for 15 
minutes.  A digital image of each gel was captured using a Kodak Gel Logic 100 
imaging system with a Fisher Biotech IT-88A transilluminator. Band intensity 
data and migration distances were obtained using Kodak 1D software, version 3.6.   
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Inductively Coupled Plasma Mass Spectrometry (ICP-MS):  After gel 
electrophoresis and staining, individual bands of ethidium-stained DNA were 
located and excised from the gel using a razor blade.  The bands were placed in 
push-top Eppendorf tubes by gel lane and digested in 1 mL 70% nitric acid.  
Samples were diluted to a volume of ~5 mL with water and analyzed on a Perkin 
Elmer Elan 6100 ICP-MS instrument.  Platinum content was measured in 
nanograms, from which the bound platinum for each lane was extrapolated. 
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RESULTS 
 
Carboplatin binding in HEPES:  Carboplatin aged for 45 hours in 0.5 M 
carbonate was reacted with pBR322 DNA for 24 hours in a 24 mM HEPES 
buffer, pH = 7.4.  After 24 hours, agarose gel electrophoresis showed significant 
changes in the mobility of both Form I and Form II DNA, Figures 1 and 2.  Form 
I, closed circular DNA, shows minimum migration at r = 0.0 and maximum 
migration at r = 1.4, with migration steadily increasing between these two r-
values.  From r = 1.4 to r = 2.8 the Form I migration distance again increases, 
though the maximum migration distance at r = 2.8 is still less than that seen with 
no drug present.  Form II nicked DNA migration distances increase with 
increasing r from r = 0.0 to r = 2.8, though the greatest changes in Form II 
migration are seen at 0.0 ≤ r ≤ 1.4.  At r = 1.4, Forms I and II have equal mobility, 
and the bands corresponding to the individual forms are indistinguishable. 
 
Figure 1:  Carboplatin bound to pBR322 plasmid DNA in HEPES buffer, stained with ethidium 
bromide.  Lane and corresponding r-value ([carboplatin]/[DNA-bp]):  1, 2.8; 2, 2.6; 3, 2.4; 4, 2.2; 5, 
2.0; 6, 1.8; 7, 1.6; 8, 1.4; 9, 1.2; 10, 1.0; 11, 0.8; 12, 0.6; 13, 0.4; 14, 0.2; 15, 0.0 (control).   
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Figure 2:  Mobility of DNA with bound carboplatin in HEPES buffer measured in arbitrary units 
(from Fig. 1).  Form I DNA indicated by circles and solid trendline (R
2
 = 0.9184); Form II DNA 
indicated by squares and dotted trendline (R
2
 = 0.9788). 
 
Carboplatin binding in HEPES plus carbonate:  Carbonate-aged carboplatin 
was reacted with pBR322 DNA under the same conditions as before, but with 24 
mM carbonate present in addition to the 24 mM HEPES buffer, pH 7.4.  After 24 
hours, gel electrophoresis showed no change in migration of Form I DNA at any 
r-value, Figures 3 and 4.  Form II DNA showed a slight increase in mobility, 
nearly indistinguishable to the naked eye, as r increased from 0.0 to 2.8.   
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Figure 3:  Carboplatin bound to pBR322 plasmid DNA in combined HEPES and carbonate buffer, 
stained with ethidium bromide.  Lane and corresponding r-value ([carboplatin]/[DNA-bp]):  1, 2.8; 2, 
2.6; 3, 2.4; 4, 2.2; 5, 2.0; 6, 1.8; 7, 1.6; 8, 1.4; 9, 1.2; 10, 1.0; 11, 0.8; 12, 0.6; 13, 0.4; 14, 0.2; 15, 0.0 
(control).   
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Figure 4: Mobility of DNA with bound carboplatin in combined HEPES and carbonate 
buffer, measured in arbitrary units (from Fig. 3).  Form I DNA indicated by circles and solid 
trendline (R
2
 = 0.041); Form II DNA indicated by squares and dotted trendline (R
2
 = 
0.8362). 
12 
Carboplating binding in HEPES plus carbonate, high r-values:  Carbonate-
aged carboplatin was again reacted with pBR322 DNA in 24 mM HEPES plus 24 
mM carbonate buffer, pH 7.4, this time with 2.0 ≤ r ≤ 10.0, Figures 5 and 6.  
Form I DNA showed a gradual decrease in migration distances with increasing r, 
similar to the trend seen at low r-values in HEPES alone but much less 
pronounced.  Form II migration seemed to increase slightly where 2.0 ≤ r ≤ 6.0, 
decreasing again for 6.5 ≤ r ≤ 10.0.   
 
 
Figure 5:  Carboplatin bound to pBR322 plasmid DNA in combined HEPES and carbonate buffer, 
stained with ethidium bromide.  Lane and corresponding r-value ([carboplatin]/[DNA-bp]):  1, 10.0; 2, 
9.5; 3, 9.0; 4, 8.5; 5, 8.0; 6, 7.5; 7, 7.0; 8, 6.5; 9, 6.0; 10, 5.5; 11, 5.0; 12, 4.5; 13, 4.0; 14, 3.5; 15, 3.0; 16, 
2.5; 17, 2.0; 18, 0.0 (control).   
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Figure 6:  Mobility of DNA with bound carboplatin in combined HEPES and carbonate buffer, 
measured in arbitrary units (from Fig. 5).  Form I DNA indicated by circles and solid trendline (R
2
 = 
0.8937); Form II DNA indicated by squares and dotted trendline (R
2
 = 0.0035). 
 
Cisplatin binding in HEPES plus carbonate, high r-values:  Cisplatin solution 
(3 mM, in 154 mM NaCl), equilibrated for 24 hours in the dark, was reacted with 
pBR322 DNA in combined HEPES/carbonate buffer at r-values of 2.0 ≤ r ≤ 10.0 
under the same conditions as the high r-value carboplatin experiment.  Gel 
electrophoresis showed a notable decrease in mobility of Form I DNA for 
increasing r over the complete range of r-values, with Form II mobility increasing 
steadily.  The mobility trends for cisplatin were more pronounced than with 
carboplatin for both DNA forms, and the change in migration of both DNA forms 
between r = 0.0 and r = 10.0 was much greater than for carboplatin. 
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Figure 7:  Cisplatin bound to pBR322 plasmid DNA in combined HEPES and carbonate buffer, 
stained with ethidium bromide.  Lane and corresponding r-value ([cisplatin]/[DNA-bp]):  1, 10.0; 2, 
9.5; 3, 9.0; 4, 8.5; 5, 8.0; 6, 7.5; 7, 7.0; 8, 6.5; 9, 6.0; 10, 5.5; 11, 5.0; 12, 4.5; 13, 4.0; 14, 3.5; 15, 3.0; 16, 
2.5; 17, 2.0; 18, 0.0 (control). 
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Figure 8:  Mobility of DNA with bound cisplatin in combined HEPES and carbonate buffer, measured 
in arbitrary units (from Fig. 7).  Form I DNA indicated by circles and solid trendline (R
2
 = 0.8912); 
Form II DNA indicated by squares and dotted trendline (R
2
 = 0.9105). 
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ICP-MS measurements of Pt bound to DNA:  For each of the binding 
experiments described above, individual bands were excised from the agarose gel 
using a razor blade, digested in nitric acid, and analyzed using ICP-MS to 
determine platinum content.  The amount of platinum (in nanograms) present in 
each lane was measured, and a general increase in platinum was shown for 
increasing r-values of both carboplatin and cisplatin.  However, platinum was 
detected in control samples which received no drug; this indicated errors in the 
technique, making all ICP-MS reading suspect and leading us to discard data thus 
collected. 
 
Binding under a CO2 atmosphere:  It was suggested that dissolved carbon 
dioxide in the carbonate buffer could be lost as CO2 gas during the drug-DNA 
incubation step.  To combat this, and ensure a consistent carbonate concentration 
throughout the 24 hour incubation, the carboplatin and cisplatin extended r-value 
experiments were repeated with a CO2 atmosphere over the drug-DNA solution.  
Control experiments were performed under nitrogen, argon, and ambient air 
atmospheres.  Various migration trends were seen, but the results could not be 
repeated and data from these experiments was discarded.  
 
Ethanol DNA precipitation:  A standard ethanol precipitation protocol (27) was 
performed to isolate platinated DNA after the 24 hour drug-DNA incubation step.  
After multiple attempts, no DNA was isolated, and this technique was abandoned. 
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DISCUSSION & CONCLUSIONS 
 
 In this study we use agarose gel electrophoresis to examine the effects of 
carbonate-aged carboplatin and cisplatin on the electrophoretic mobility of 
pBR322 plasmid DNA when binding is carried out in carbonate media.  Since this 
gel technique does not require any work-up of the metalated DNA prior to gel 
analysis, it is especially well suited for Pt-DNA binding studies involving 
carbonate buffer. 
 Our preliminary study, testing the DNA binding of carbonate-aged 
carboplatin at low r-values, showed distinct migration changes when reaction 
took place in HEPES buffer only.  The initial decrease of Form I mobility, 
followed by co-migration with Form II, then increased mobility, corresponds with 
trends seen for both cisplatin (9,21,22) and carboplatin (5,6) in previous gel 
electrophoresis studies.  Using carbonate-activated carboplatin at low 
concentration, we were able to see migration patterns which were only observed 
using lengthy incubation times (6) or much higher drug concentrations (5) in prior 
studies on native carboplatin.  Since platinum binding does not significantly affect 
the total charge of the DNA molecule, the observed changes in mobility are due to 
changes in the degree of supercoiling of DNA as would occur through formation 
of a 1,2-intrastrand crosslink.  This result indicates that carbonate-aged 
carboplatin contains a greater number of DNA-reactive compounds than 
unmodified carboplatin, as was suggested by Di Pasqua et. al. (23).   
17 
 Our observations with carboplatin showed some key differences compared 
with earlier cisplatin studies.  First, while the “coalescence point” (where Form I 
and Form II migrate to the same point on the gel) occurs at r = 1.4, this point does 
not seem to correspond to the migration for DNA with zero supercoiling (Form II 
when r = 0.0) as it did for Keck and Lippard (9).  Second, the staining intensity 
trends seen here differ from those found in cisplatin studies (21).  In our study, 
Form I intensity decreased with increasing drug concentration, opposite the 
published cisplatin trend.  These observations may highlight differences between 
carboplatin and cisplatin DNA interactions. 
 When carbonate-activated carboplatin was reacted with DNA at low r-
values in carbonate media, there were no readily-apparent changes in migration 
indicative of drug binding.  Form I DNA showed the same migration for all r-
values, while Form II migration increased a slight amount as r increased.  This 
trend corresponds well with prior observations on the binding of cisplatin at 
similar r-values in carbonate media (21,22).  From our observations, the 24 mM 
carbonate present in the reaction buffer was enough to prevent DNA binding of 
the drug.  Here again, intensity decreased for Form I, counter to trends published 
for cisplatin studies. 
 Carbonate-aged carboplatin is known to contain carbonato/bicarbonato 
complexes (23); when the activated drug is added to a carbonate-free medium, 
these species lose CO2 through mass action effects (28).  This equilibrium shift 
results in the formation of aquo/hydroxo species, which are able to bind DNA via 
the formation of 1,2-intrastrand crosslinks, unwinding Form I supercoiled DNA 
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and leading to the migration patterns here seen in HEPES alone.  The addition of 
carbonate to the system blocks this process.  At low drug concentration, the 
dissolved CO2 in our 24 mM carbonate buffer is enough to prevent the loss of 
CO2 from the carbonato/bicarbonato species of carbonate-aged carboplatin.  The 
monoaquo species required for DNA binding cannot form, and thus DNA binding 
is blocked by the presence of carbonate.  This leads to the lack of mobility change 
in HEPES/carbonate buffer when r ≤ 2.8. 
 In order to determine whether the inhibitory effect of carbonate could be 
overcome by high concentrations of activated carboplatin, we extended the r-
values to a maximum of r = 10.0.  At very high carboplatin doses, mobility 
changes were seen which indicated that the 1,2-intrastrand crosslink was forming 
despite the presence of 24 mM carbonate.  This finding indicated that carbonate 
blocks the formation of the standard bifunctional adduct at low drug 
concentration; however, if the carboplatin concentration is increased with constant 
carbonate concentration, the equilibrium is shifted toward formation of 
aquo/hydroxo DNA binding species. 
 Following the publication of Dabrowiak and coworkers’ initial report 
describing cisplatin binding to pBR322 DNA in carbonate buffer (21), Todd et. al. 
(22) further investigated binding in this system by increasing drug concentrations 
to r > 3.13.  Using different techniques, they found that cisplatin can bind to 
closed circular DNA and unwind the superhelical structure even in the presence of 
carbonate.  Their conclusion was that, while carbonate inhibits cisplatin binding, 
it does not change the type of platinum adduct which forms, and the 1,2-
19 
intrastrand crosslink is capable of forming in both carbonate and carbonate-free 
systems. 
 Our results indicate that 1,2-intrastrand crosslinking occurs only at low 
ratios of cisplatin concentration to carbonate concentration.  Since these 
conditions shift the equilibrium in favor of cisplatin aquo/hydroxo species, the 
observed binding is likely due to the interaction of the aquo/hydroxo species with 
DNA.  As seen on our cisplatin gel, at high r-values the migration of Form I 
decreases while Form II migration increases, in a manner identical to that seen 
with no carbonate in the system (21).  As with carboplatin, cisplatin in carbonate 
media forms carbonato complexes (19); these neutral or anionic species do not 
bind to DNA.  The dissolved CO2 present in carbonate buffer prevents aquated 
cisplatin species from forming and binding to DNA, and thus cisplatin binding 
can only occur when drug concentration is high enough to overcome carbonate’s 
blocking effect.  As with our carboplatin studies, the cisplatin staining intensity of 
Form I DNA decreased with increasing r-value, counter to prior published 
findings (21). 
 In an effort to prevent off-gassing of CO2 from the carbonate buffer during 
the 24 hour drug/DNA incubation, several experiments were attempted which 
involved keeping an atmosphere of CO2 gas over the reaction solution.  This, it 
was theorized, would prevent the loss of dissolved carbon dioxide from the buffer, 
maintaining a consistent carbonate concentration throughout the experiment.  
Migration trends could not be replicated in these experiments, and studies using 
inert gases proved equally inconclusive (data not shown).  Attempts at 
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quantitatively describing the carbonate effect were similarly challenging.  
Excising DNA bands from stained gels and analyzing them for platinum content 
showed logical trends, where measured platinum content increased with 
increasing r-values.  However, platinum was detected in samples which had not 
received any amount of carboplatin or cisplatin.  This indicated that our control 
samples were being contaminated with platinum from some source, making the 
data untrustworthy (data not shown).  Attempts at performing a standard ethanol 
DNA precipitation method were unsuccessful, and no DNA was isolated from the 
reaction samples.   
 Despite these difficulties, our gel electrophoresis findings give a reliable 
portrait of the effect of carbonate buffer on the DNA binding of these two 
platinum drugs.  As mentioned, a strength of this electrophoresis technique is that 
it requires no isolation or treatment of the platinated DNA, eliminating the 
possibility of changing or removing platinum adducts through intermediate 
workup steps.  Further, the carbonate aging process used to activate carboplatin 
provides modified drug species in the varieties and relative amounts which may 
form in vivo, while removing guesswork by not requiring us to identify individual 
species and concentrations.  The system models the proposed in vivo activation 
mechanism from start to finish, operating on biochemical principles rather than 
operator input. 
 The system we have constructed carries out DNA binding under 
conditions identical to those of the human body in terms of carbonate 
concentration, H
+
 ion concentration, and temperature.  The carboplatin activation 
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step preceding DNA binding strays from strict physiological conditions with 
significantly increased reaction times and carbonate concentrations; these 
conditions are employed to provide a surplus of the carbonate-modified species 
expected to form in the blood stream.  Overall, our system establishes a model 
which is similar to the DNA binding environment of both cisplatin and 
carboplatin, providing a relevant system to carry out studies on these two drugs. 
 In conclusion, our findings show that DNA binding of cisplatin and 
carbonate-activated carboplatin is affected by the presence of carbonate buffer at 
physiologically relevant concentrations.  In particular, our high r-value studies 
show that the formation of the conventional 1,2-intrastrand crosslink is negatively 
influenced by the presence of carbonate for both drugs.  Since 
carbonato/bicarbonate complexes can form by attack from carbonate, the presence 
of this material in the biological system may control the concentration of 
biologically reactive metal aquo species of cisplatin and carboplatin and their 
reactivity with targets including DNA.  Clearly, elucidating the complex 
equilibria associated with these important reactions requires further investigation.  
This work demonstrating the role of carbonate in the mechanism of action of 
platinum anticancer drugs shows the importance of studying drug activity under 
biologically relevant conditions, and it is our hope that such investigations will 
continue in the field of anticancer drug research. 
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